Trial · NCT02772419
Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis
NCT02772419, Phase 2, Completed, Kyowa Kirin Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis. Trials, record NCT02772419. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02772419
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis
- NCT number
- NCT02772419
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 63 participants, actual
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Conditions
- Eosinophilic Chronic Rhinosinusitis
- Interventions
- benralizumab, benralizumab, Placebo
- First posted
- 2016-05-13
- Last updated
- 2018-04-23
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The change from baseline in nasal polyp score at Week 12 | baseline and 12 weeks post-dose | |
| Secondary | The change from baseline in nasal polyp score | Pre-dose and 4,8,12,16,20,24 weeks post-dose | |
| Secondary | The change from baseline in Computed tomography (CT) score | baseline and 12 weeks post-dose | |
| Secondary | Number of subjects discontinued from the study due to aggravation of eosinophilic chronic rhinosinusitis | Up to 24 weeks after dosing | |
| Secondary | Time to discontinuation (days) from the study due to aggravation of eosinophilic chronic rhinosinusitis | Up to 24 weeks after dosing | |
| Secondary | The change from baseline in Blood eosinophil count | Pre-dose and 4,8,12,16,20,24 weeks post-dose | |
| Secondary | The change from baseline in Nasal Airway Resistance | Pre-dose and 4,8,12,24 weeks post-dose | Nasal airway resistance (Pa/cm\^3/s) |
| Secondary | The change from baseline in the averaged values of the Olfactory thresholds | Pre-dose and 4,8,12,24 weeks post-dose | Olfactory thresholds are assessed by T\&T Olfactometer Test Score (Five kinds of smell with eight (5 to -2) phases). |
| Secondary | The change from baseline in the improvement of olfactory dysfunction | Pre-dose and 4,8,12,24 weeks post-dose | Olfactory dysfunction (1 to 5) is calculated by the Olfactory thresholds. |
| Secondary | The change from baseline in Sino-Nasal Outcome Test-2 (SNOT-22) | Pre-dose and 4,8,12, 16, 20, 24 weeks post-dose | Symptom score are assessed by VAS (nasal congestion, anterior and posterior nasal drip, loss of the sense of smell, headache, and impairment in activity of daily living) |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 25945591 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02772419
GET https://conductscience.org/api/trials/v1/NCT02772419/registered